SCENESSE® dosage expansion under review by European Medicines Agency 2024 Announcements . Clinical . News . Regulatory 20.11.2024
CLINUVEL prioritises three strategic programs 2024 Announcements . Clinical . News . Regulatory 18.11.2024
CLINUVEL files Canadian New Drug Submission for SCENESSE® in EPP 2024 Announcements . Clinical . News . Regulatory 01.10.2024
SCENESSE® data to be presented at global porphyria conference 2024 Announcements . Clinical . News . Regulatory 20.09.2024
Afamelanotide assists DNA repair response following UV radiation 2024 Announcements . Clinical . News 05.07.2024
SCENESSE® European Orphan Drug Designation for Variegate Porphyria 2024 Announcements . Clinical . News 24.06.2024
Technical note: Afamelanotide as MC1R-targeted therapy in Parkinson’s [PD] 2024 Announcements . Clinical . News 18.06.2024
CLINUVEL withdraws SCENESSE® label expansion for adolescent erythropoietic protoporphyria 2024 Announcements . Clinical . News 03.06.2024
SCENESSE® efficacy in vitiligo: new case presented at AAD 2024 Announcements . Clinical . News . Regulatory 11.03.2024
SCENESSE® provides photoprotection, improves QoL in variegate porphyria 2024 Announcements . Clinical . News . Regulatory 04.03.2024